Actavis has begun shipping Clobetasol Propionate Shampoo and Clobetasol Propionate Lotion, generic equivalents to Galderma’s Clobex® Shampoo and Clobex® Topical Lotion.

The FDA has granted Actavis a 180-day marketing exclusivity, due to Actavis’ first-to-file status.

According to IMS Health, combined annual brand sales of Clobex Shampoo and Clobex Topical Lotion were USD89.9 million for the 12 months ending 30 September 2011.

Doug Boothe, CEO of Actavis US, said:
“The launch of Clobetasol Propionate Shampoo and Clobetasol Propionate Lotion displays our continuing commitment to introduce new, high quality generic products to the marketplace, as well as highlights our expertise in developing and manufacturing a wide range of dosage forms. Actavis’ drive to be a leader in generic pharmaceuticals is supported by one of the largest product development pipelines in the industry.”